Abbott shares rise after securing first win in premature infant formula trial
Nov 1 (Reuters) -Abbott Laboratories ABT.N shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over their premature baby formulas' risks.
A jury in St. Louis, Missouri found on Thursday that Abbott and Reckitt RKT.L unit Mead Johnson are not responsible for a young boy's severe intestinal disease, marking the first victory for the companies after large losses in two previous trials.
The lawsuit was one of about 1,000 similar cases pending nationwide over allegations the companies failed to warn that their specialized formulas used by newborn intensive care units in hospitals could cause necrotizing enterocolitis (NEC).
NEC almost exclusively affects premature infants and has an estimated mortality rate of more than 20%.
After the verdict and the "overwhelming societal support of infant formula, we think its prudent to lower the liability exposure and raise the odds of an Abbott victory in the trials, or at least improve the company's negotiating power in a settlement," J.P.Morgan analyst Robbie Marcus said in a note.
Marcus said investors were assuming a potential liability of $2 billion to $3 billion in NEC-related cases and the win could reduce Abbott's total liability by $500 million to $1 billion.
Verdicts in two lawsuits had already led to settlements of $60 million against Mead and $495 million against Abbott.
After that, however, U.S. regulatory agencies and some scientists convened by the National Institutes of Health said current evidence does not support the hypothesis that the formula causes NEC.
While the companies were not allowed to present the agencies' statement to the jury in the latest trial, Evercore analyst Vijay Kumar said it further strengthens Abbott's position in NEC-related lawsuits.
Abbott shares are priced at 24.25 times their estimated earnings for the next 12 months, a common benchmark for valuing stocks, compared with 14.73 for Reckitt.
Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
